Eli Lilly Shares Rise Following Positive Clinical Trial Results for Retatrutide and Foundayo
Eli Lilly (LLY) shares saw upward momentum following positive clinical trial data regarding its GLP-1 drug pipeline. Recent Phase 3 results for retatrutide demonstrated significant efficacy in reducing knee osteoarthritis pain, alongside substantial weight loss. Additionally, the company announced that its drug Foundayo significantly reduced breathing interruptions in patients with obstructive sleep apnea by up to 44%, with an FDA submission planned by year-end. The company is also expanding market access through a new agreement with Hims & Hers Health (HIMS) to offer Zepbound and Foundayo on their platform. Despite high valuation multiples, Lilly's strong financial performance—highlighted by a 39% third-quarter revenue increase to $24.4 billion—and raised full-year guidance suggest robust growth driven by the expanding therapeutic applications of GLP-1 medications.
Topics: clinical trials GLP-1 drugs obstructive sleep apnea osteoarthritis weight loss
Read the full article at Motley Fool
Part of the story Eli Lilly Shares Rise Following Positive Clinical Trial Results for Retatrutide and Foundayo (4 articles)